Reduced Drug Use and Hospitalization Rates in Patients Undergoing Hemodialysis Who Received Pharmaceutical Care: A 2‐Year, Randomized, Controlled Study
Authors:
- 1 December 2009
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 29 (12) , 1433-1440
Abstract
Study Objective. To investigate the impact of a pharmaceutical care program managed by clinical pharmacists on drug use, drug costs, hospitalization rates, and drug‐related problems (DRPs) in ambulatory patients undergoing hemodialysis.Design. Prospective, randomized, controlled, longitudinal, 2‐year pilot study.Setting. Nonprofit university‐affiliated dialysis clinic.Patients. One hundred four patients older than 18 years with end‐stage renal disease (ESRD) who were undergoing a stable hemodialysis regimen for at least 3 months.Intervention. Patients were randomly assigned to receive either pharmaceutical care, consisting of one‐on‐one care, with in‐depth drug therapy reviews conducted by a clinical pharmacist (57 patients), or standard of care, consisting of brief drug therapy reviews conducted by a nurse (47 patients).Measurements and Main Results. Baseline data on demographic and clinical characteristics were collected. Mean numbers of concomitant drugs, drug costs, hospitalization rates, and lengths of stay were compared between the groups. In the pharmaceutical care group, DRPs were identified and recorded. Baseline age, length of time receiving hemodialysis, and etiology of ESRD were not significantly different between the groups. Mean number of concomitant drugs at baseline was similar between the groups. At the end of the 2‐year follow‐up, pharmaceutical care was associated with a significant decrease of 14% fewer drugs compared with standard of care, as documented during each drug therapy review (pConclusion. Identification and resolution of DRPs through pharmaceutical care resulted in decreased drug use and costs for patients undergoing hemodialysis. Hospitalization rates were significantly lower in the pharmaceutical care group, with a trend toward shorter duration. Provision of pharmaceutical care is associated with tangible benefits on outcomes in ambulatory patients undergoing hemodialysis and should be considered in health care policy decisions.Keywords
This publication has 10 references indexed in Scilit:
- Health‐related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: A 2‐year randomized, controlled studyHemodialysis International, 2009
- Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patientsKidney International, 2007
- Medication-related problem type and appearance rate in ambulatory hemodialysis patientsBMC Nephrology, 2003
- Factors associated with medication-related problems in ambulatory hemodialysis patientsAmerican Journal of Kidney Diseases, 2003
- Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomesKidney International, 2002
- Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness ModelJournal of the American Pharmaceutical Association, 2001
- Drug‐Related Hospital AdmissionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1996
- Chronic Hemodialysis Patients. Part II: Reducing Drug-Related Problems through Application of the Focused Drug Therapy Review ProgramAnnals of Pharmacotherapy, 1994
- Chronic Hemodialysis Patients. Part I: Characterization and Drug-Related ProblemsAnnals of Pharmacotherapy, 1994
- Drug-Related Problems: Their Structure and FunctionDICP, 1990